Prosecution Insights
Prosecution Insights
17 pending office actions • 5 clients • 16 examiners • 10 art units • 0 of 17 (0%) have an AI response strategy ready • 20 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 17 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 17 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 11 (65%) |
| §102 only | 1 (6%) |
| No statute on record | 5 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIRAKIS, SOPHIA P | 2 | 41.2% | +74.1% |
| CHICKS, ASHLI ARIANA | 1 | 64.1% | +44.9% |
| ANDERSON, REBECCA L | 1 | 73.2% | +24.0% |
| RAO, PADMAJA S | 1 | 69.5% | +35.9% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.4% | +41.3% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.3% | +48.6% |
| PURDY, KYLE A | 1 | 40.8% | +36.8% |
| LEE, CHIHYI NMN | 1 | 32.5% | +62.8% |
| HEITMEIER, KENDALL NICOLE | 1 | 65.5% | +30.4% |
| GAUGER, PAUL RANDALL | 1 | 62.5% | -14.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18031077 | PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | TOWNSLEY, SARA ELIZABETH | 13d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17801709 | POTENT AND SELECTIVE DEGRADERS OF ALK | HEITMEIER, KENDALL NICOLE | 182d overdue |
| 17773992 | SELECTIVE DUAL HISTONE DEACETYLASE 6/8 (HDAC6/8) DEGRADERS AND METHODS OF USE THEREOF | HIRAKIS, SOPHIA P | 49d overdue |
| 18215286 | INHIBITORS OF TRIM33 AND METHODS OF USE | ANDERSON, REBECCA L | 42d overdue |
| 17772384 | SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | HIRAKIS, SOPHIA P | 23d overdue |
| 18269122 | SMALL MOLECULE DEGRADERS OF PHOSPHATIDYLINOSITOL-5-PHOSPHATE 4-KINASE TYPE 2 AND USES THEREOF | RAO, PADMAJA S | 4d overdue |
| 18031077 | PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | TOWNSLEY, SARA ELIZABETH | 13d |
| 18033872 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | ABDALHAMEED, MANAHIL MIRGHANI ALI | 22d |
| 18001995 | PROTEIN TAG TO INDUCE LIGAND DEPENDENT DEGRADATION OF PROTEIN/PROTEIN-FUSIONS | PURDY, KYLE A | 26d |
| Client (Assignee) | Pending OAs |
|---|---|
| DANA-FARBER CANCER INSTITUTE, INC. | 13 |
| Yeda Research And Devlopment Co. Ltd. | 1 |
| Columbia University | 1 |
| KIST | 1 |
| NEOMORPH, INC. | 1 |
| Art Unit | Apps |
|---|---|
| 1621 | 3 |
| 1626 | 2 |
| 1627 | 2 |
| 1622 | 2 |
| 1629 | 2 |
| 1623 | 2 |
| 1611 | 1 |
| 1628 | 1 |
| 1625 | 1 |
| 1631 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18281861 | INHIBITORS OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE (PIN1) AND USES THEREOF | Yeda Research And Devlopment Co. Ltd. | CHICKS, ASHLI ARIANA | 1626 | Other | Non-Final OA | 54d | Pending | Sep 13, 2023 |
| 18215286 | INHIBITORS OF TRIM33 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | ANDERSON, REBECCA L | 1626 | §103 | Non-Final OA | 42d overdue | Pending | Jun 28, 2023 |
| 18269122 | SMALL MOLECULE DEGRADERS OF PHOSPHATIDYLINOSITOL-5-PHOSPHATE 4-KINASE TYPE 2 AND USES THEREOF | Cornell University | RAO, PADMAJA S | 1627 | §103 | Non-Final OA | 4d overdue | Pending | Jun 22, 2023 |
| 18033872 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | Korea Institute Of Science And Technology (Kist) | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103 | Final Rejection | 22d | Pending | Apr 26, 2023 |
| 18031077 | PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | Neomorph, Inc. | TOWNSLEY, SARA ELIZABETH | 1629 | — | Final Rejection | 13d | Pending | Apr 10, 2023 |
| 18001995 | PROTEIN TAG TO INDUCE LIGAND DEPENDENT DEGRADATION OF PROTEIN/PROTEIN-FUSIONS | DANA-FARBER CANCER INSTITUTE, INC. | PURDY, KYLE A | 1611 | §103 | Final Rejection | 26d | Pending | Dec 15, 2022 |
| 17926074 | PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | LEE, CHIHYI NMN | 1628 | Other | Non-Final OA | 34d | Pending | Nov 17, 2022 |
| 17801709 | POTENT AND SELECTIVE DEGRADERS OF ALK | DANA-FARBER CANCER INSTITUTE, INC. | HEITMEIER, KENDALL NICOLE | 1621 | §103 | Final Rejection | 182d overdue | Pending | Aug 23, 2022 |
| 17774002 | SELECTIVE HISTONE DEACETYLASE (HDAC) DEGRADERS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | GAUGER, PAUL RANDALL | 1629 | §103 | Final Rejection | 31d overdue | Pending | May 03, 2022 |
| 17773992 | SELECTIVE DUAL HISTONE DEACETYLASE 6/8 (HDAC6/8) DEGRADERS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | HIRAKIS, SOPHIA P | 1623 | §103 | Final Rejection | 49d overdue | Pending | May 03, 2022 |
| 17772384 | SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | HIRAKIS, SOPHIA P | 1623 | Other | Final Rejection | 23d overdue | Pending | Apr 27, 2022 |
| 17642495 | KDM INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | RZECZYCKI, PHILLIP MATTHEW | 1625 | §102 | Non-Final OA | 3d overdue | Pending | Mar 11, 2022 |
| 17580190 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. | LEONARD, ARTHUR S | 1631 | §103 | Final Rejection | 93d overdue | Pending | Jan 20, 2022 |
| 17601605 | DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) | DANA-FARBER CANCER INSTITUTE, INC. | BAUER, NICOLA MARIA | 1621 | §103 | Final Rejection | 58d overdue | Pending | Oct 05, 2021 |
| 17419965 | SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN dTAG SYSTEMS | DANA-FARBER CANCER INSTITUTE, INC. | YOO, SUN JAE | 1621 | §103 | Non-Final OA | 15d overdue | Pending | Jun 30, 2021 |
| 17284250 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | DANA-FARBER CANCER INSTITUTE, INC. | LADD, CAROLYN LOUISE | 1622 | Other | Non-Final OA | 25d overdue | Pending | Apr 09, 2021 |
| 17265139 | HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | PECKHAM, RICHARD GRANT | 1627 | §103 | Final Rejection | 42d overdue | Pending | Feb 01, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial